Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/29669
Title: Prescription Patterns and Testosterone Concentrations Achieved With AndroForte 5% Testosterone Cream in Transgender and Gender Diverse Individuals.
Austin Authors: Nolan, Brendan James ;Zwickl, Sav;Locke, Peter;Simpson, Satu;Li, Ling;Zajac, Jeffrey D ;Cheung, Ada S 
Affiliation: Equinox Gender Diverse Clinic, Thorne Harbour Health, Abbotsford, Victoria, Australia..
Endocrinology
Medicine (University of Melbourne)
Issue Date: Jun-2022
Date: 2022-03-30
Publication information: The Journal of Sexual Medicine 2022; 19(6): 1049-1054
Abstract: Masculinizing hormone therapy with testosterone is used to align an individual's physical characteristics with their gender identity in trans and gender diverse individuals. Standard testosterone doses and formulations recommended for hypogonadal cisgender men are typically administered. 100 mg AndroForte 5% testosterone cream is the recommended starting dose in hypogonadal cisgender men but there are no data evaluating the use of AndroForte 5% testosterone cream in gender-affirming hormone therapy regimens. To assess the prescription patterns and serum total testosterone concentrations achieved with AndroForte 5% testosterone cream in trans and gender diverse individuals. A retrospective analysis was undertaken of trans and gender diverse individuals at a primary and secondary care clinic in Melbourne, Australia. Seventy-two individuals treated with AndroForte 5% testosterone cream to the torso were included. Testosterone dose and serum total testosterone concentration. Median age was 26 years (IQR 22-30) and median duration of testosterone therapy was 14 months (7-24). Fifty (69%) individuals had a non-binary gender identity. Initial median testosterone dose was 50 mg (50-100) daily. Thirty-eight (53%) commenced doses <100 mg daily, the recommended starting dose for hypogonadal cisgender men. Median total testosterone concentration achieved from 186 individual laboratory results was 11.9 nmol/L (8.1-16.4). Polycythemia was documented in 5 (7%) individuals. AndroForte 5% testosterone cream can be used in individuals with a binary and/or non-binary gender identity seeking masculinization. It can be commenced at a lower dose than that administered to hypogonadal cisgender men for individuals seeking slow masculinization goals. Limitations include the retrospective study design, lack of clinical end points and lack of standardization of timing of laboratory tests in relation to the last dose. This is the first study to evaluate AndroForte 5% testosterone cream in trans and gender diverse individuals and provides insights into prescription patterns in individuals with a non-binary gender identity. AndroForte 5% testosterone cream represents an alternative formulation of testosterone administration for trans and gender diverse individuals seeking masculinization. Nolan BJ, Zwickl S, Locke P, et al. Prescription Patterns and Testosterone Concentrations Achieved With AndroForte 5% Testosterone Cream in Transgender and Gender Diverse Individuals. J Sex Med 2021;XX:XXX-XXX.
URI: https://ahro.austin.org.au/austinjspui/handle/1/29669
DOI: 10.1016/j.jsxm.2022.02.020
ORCID: 0000-0001-8836-165X
0000-0003-2959-5928
0000-0003-3933-5708
0000-0001-5257-5525
Journal: The journal of sexual medicine
PubMed URL: 35365401
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35365401/
Type: Journal Article
Subjects: Gender Identity
Non-Binary
Testosterone
Transdermal
Transgender
Appears in Collections:Journal articles

Show full item record

Page view(s)

54
checked on Jun 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.